ANHEDONIA and Promethazine


ANHEDONIA Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for ANHEDONIA

ANHEDONIA treatment research studies

Promethazine clinical trials, surveys and public health registries

Find Drug Side Effect reports

Promethazine Side Effects

Poisoning (63)
Toxicity To Various Agents (47)
Pain (45)
Nausea (37)
Completed Suicide (36)
Cardiac Arrest (36)
Cholecystitis Chronic (36)
Respiratory Arrest (34)
Confusional State (33)
Anxiety (27)
Vomiting (24)
Dyspnoea (24)
Exposure Via Ingestion (23)
Cholelithiasis (21)
Convulsion (21)
Injury (20)
Gallbladder Disorder (19)
Death (19)
Abdominal Pain (19)
Agitation (18)
Cardio-respiratory Arrest (18)
Dizziness (18)
Pain In Extremity (18)
Tremor (16)
Dystonia (16)
Diarrhoea (16)
Abdominal Pain Upper (15)
Dehydration (15)
Dyskinesia (15)
Mental Status Changes (15)
Headache (15)
Unresponsive To Stimuli (14)
Hallucination (14)
Emotional Distress (13)
Fatigue (13)
Hypotension (12)
Gait Disturbance (12)
Extrapyramidal Disorder (11)
Somnolence (11)
Oedema Peripheral (11)
Dysarthria (10)
Depression (10)
Deep Vein Thrombosis (10)
Burning Sensation (10)
Erythema (10)
Hypertension (10)
Pulmonary Embolism (10)
Lethargy (10)
Injection Site Pain (10)
Hypoaesthesia (10)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

ANHEDONIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Depression and Dopamine Transporter Function Study Using C-11 Altropane
Conditions: Major Depressive Disorder;   Anhedonia
Outcome Measures: 11C-Altropane Binding;   Behavioral Performance in Probabilistic Reward Task;   Brain Activity during Instrumental Learning Task;   Behavioral Performance in Instrumental Learning Task;   Behavioral Performance in the Social Reinforcement Learning Task;   Questionnaire Data;   Behavioral Performance in Implicit Learning Serial Reaction Time Task
2 Recruiting Effects of Quitting Study A Test of Pre-clinical Findings
Condition: Smoking
Intervention: Behavioral: Smokers cease smoking
Outcome Measures: Responses to Effort Expenditure for Rewards Task (EEfRT) Test;   Rewarding Events Scale score.;   Delayed Discounting;   Self-reports of Anhedonia and Apathy
3 Recruiting Effects of Bupropion in Depression
Condition: Depression
Intervention: Drug: Bupropion
Outcome Measures: Change in haemodynamic (i.e. BOLD signal) response;   Change in questionnaire measures of subject mood and Anhedonia;   Change in accuracy and reaction time
4 Recruiting Brain Mechanisms of Emotion and Motivation: A Mind-Body Study
Conditions: Acute Stress;   Anhedonia;   Healthy
Outcome Measures: Brain Activity during Instrumental Learning Task;   Change in Behavioral Performance in Instrumental Learning Task;   Behavioral performance in Effort-Expenditure for Rewards Task;   Change in Questionnaire Data;   Change in Behavioral Performance in Probabilistic Reward Task;   Life Events and Difficulties (LEDS) interview;   Change in salivary hormone levels;   Salivary genetic analysis;   Change in inflammatory cytokine levels in blood plasma;   Behavioral Performance in Instrumental Learning Task;   Change in Behavioral performance in Reaction Time task
5 Recruiting The Effect of CBT- Based Weight Loss Program on Eating Behavior, Weight Loss Result and Risk for Coronary Heart Diseases and Type 2 Diabetes
Conditions: Obesity;   Hypercholesterolemia;   Diabetes Mellitus, Type 2;   Anhedonia
Intervention: Behavioral: Cognitive behavioral therapy -based weight loss program
Outcome Measures: change in weight;   change in eating behavior;   change in total cholesterol,HDL, LDL,Trigly and glucose;   DNA;   change in incretins
6 Unknown  Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)
Conditions: Abnormal Mental State;   Schizophrenia
Intervention: Drug: Quetiapine(Seroquel-XR) 50~800mg a day
Outcome Measures: California Verbal Learning Test;   verbal & spatial 2-back test, Digit Span, 3-7 CPT, WCST, Rey-CFT, TMT A & B, COWAT, SOPS, PANSS, SAS, PAS, AIHQ, BIS
7 Recruiting Nicotine Withdrawal Symptoms and Smoking Relapse
Condition: Nicotine Dependence
Outcome Measures: Change in BOLD signal and FC related to task parameters, Behavioral performance, and Self-reported craving, withdrawal symptoms and mood/affect.;   MRS for glutamate concentration, Plasma ACTH and cortisol, Resting state CBF, ERP and EEG measures, craving and physiological responses to physical drug cues, self-report characterization measures, & amp; structural MRI and DTI data.
8 Unknown  Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy
Conditions: Chronic Pain;   Opioid Abuse, Unspecified Use
Interventions: Behavioral: Mindfulness-Oriented Recovery Enhancement;   Behavioral: Conventional Support Group (SG)
Outcome Measures: Pain severity, pain functional interference;   Opioid craving;   Opioid misuse behaviors;   Well-being;   Attentional bias;   Psychophysiological cue-reactivity;   Emotional response inhibition;   Pain coping strategies;   Anhedonia;   Fear of pain;   Mindfulness;   Positive reappraisal
9 Recruiting Deep Brain Stimulation (DBS) for the Management of Treatment Refractory Negative Symptoms in Schizophrenia
Condition: Schizophrenia; Negative Type
Intervention: Procedure: Deep Brain Stimulation
Outcome Measure: Schedule for the Assessment of Negative Symptoms (SANS)
10 Unknown  Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa
Condition: Anorexia Nervosa
Intervention: Procedure: Deep Brain Stimulation
Outcome Measures: Eating Disorder Related Preoccupations and Rituals;   Depression;   Anxiety;   Quality of Life
11 Unknown  Chronic Cannabis Users: A Model for Negative Symptoms in Schizophrenia
Conditions: Chronic Cannabis Users;   Healthy Subjects
Interventions: Procedure: Magnetoencephalograph (MEG);   Behavioral: Cambridge Neuropsychological Test Automated Battery (CANTAB).;   Behavioral: Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)
Outcome Measures: Clinical Measure;   Cognitive Measure;   Electrophysiological Measure
12 Recruiting Recognition and Early Intervention on Prodrome in Bipolar Disorders
Condition: Bipolar Disorder
Interventions: Other: aerobic exercise;   Other: psychoeducation
Outcome Measures: Change from Baseline in Clinical Global Impressions (CGI) Scale at 12 weeks;   Diagnostic status;   Change from Baseline in Hamilton Depression Rating Scale at 12 weeks;   Change from baseline in Young Mania Rating Scale at 12 weeks;   Change from baseline in Brief Psychiatric Rating Scale at 12 weeks;   Change from baseline in Hamilton Anxiety Rating Scale at 12 weeks;   Change from baseline in Global Assessment Scale at 12 weeks
13 Recruiting Comparative Study of Physiological and Cerebrovascular Reactivity in Depression, at the Three Phases of Emotion
Condition: Major Depressive Disorder
Interventions: Behavioral: psychometric tests;   Device: MRI;   Device: transcranial doppler and TPI;   Behavioral: explicitative interview
Outcome Measures: amplitude variations of heart and respiratory rate, cerebral pulsatility, galvanic skin response and startle as measure of physiological reactivity;   MRI data as measure of cerebral perfusion, volume of leukoaraiosis and default network (fMRI at rest);   ultrasound data of doppler as measure of cerebral pulstility;   score of psychometric tests as measure of emotional state;   spontaneous verbal production to emotional pictures and explicitative interviews